Transdermal Nicotine and Bupropion in Schizophrenics
Principal Investigator
|
Assistant Professor (Research) |
Funding Source
NIDA
Description
This project is supported by a NIDA R01 grant that was awarded to Dr. Tidey in 2001 and is in its final year of funding. The overall aim of this human laboratory project is to investigate some biological and environmental mechanisms that may account for the high prevalence of smoking and low smoking quit rates in people with schizophrenia. The project encompasses two studies in which we are comparing the effects of acute smoking abstinence, smoking cue exposure, transdermal nicotine and bupropion-SR in smokers with schizophrenia and equally-heavy smokers who do not have a psychiatric illness. Outcome measures include smoking urges, nicotine withdrawal symptoms, measures of smoking topography, and choices for smoking versus receiving another reinforcer. The co-investigators on this project are Drs. Rohsenow, Swift and Kaplan. We anticipate beginning the continuation of this project in early 2006. The continuation will involve testing the separate and combined effects of nicotine replacement and behavioral replacement for smoking on smoking, urges, nicotine withdrawal symptoms and other measures in people with schizophrenia versus non-psychiatric controls.